Get the Stockscreener App
1.15
0.00%
0.00
After Hours:
1.13
-0.02
-1.74%
Lucid Diagnostics Inc stock is traded at $1.15, with a volume of 587.73K.
It is up +0.00% in the last 24 hours and down -20.14% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$1.15
Open:
$1.15
24h Volume:
587.73K
Relative Volume:
0.48
Market Cap:
$195.92M
Revenue:
$4.71M
Net Income/Loss:
$-58.01M
P/E Ratio:
-1.3966
EPS:
-0.8234
Net Cash Flow:
$-46.68M
1W Performance:
-4.17%
1M Performance:
-20.14%
6M Performance:
+13.86%
1Y Performance:
-22.82%
1-Day Range:
$1.14
$1.1898
1-Week Range:
$1.09
$1.25
52-Week Range:
$0.9495
$1.80
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.15 | 195.92M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Update - MarketBeat
Dow Update: Can Lucid Diagnostics Inc be recession proof2026 Key Highlights & Accurate Intraday Trade Tips - baoquankhu1.vn
Lucid Diagnostics’ Earnings Call: Momentum Amid Cash Strain - The Globe and Mail
LUCD: BTIG Reiterates Buy Rating with $2.50 Price Target | LUCD Stock News - gurufocus.com
Profit Review: Whats the MACD signal for Lucid Diagnostics Inc2026 Trends & Scalable Portfolio Growth Ideas - baoquankhu1.vn
PAVmed Reports 2025 Financial Results, Strengthens Capital Structure, and Expands Medical Device Portfolio Under New Leadership - Minichart
Lucid Diagnostics (NASDAQ:LUCD) Earns Buy Rating from BTIG Research - MarketBeat
PAVmed (NASDAQ: PAVM) overhauls capital structure and reports 2025 results - Stock Titan
Lucid Diagnostics (LUCD) Earnings Transcript - AOL.com
Cancer screening test wins VA access for 9 million veterans - Stock Titan
BTIG reiterates Lucid Diagnostics stock rating on Q4 beat By Investing.com - Investing.com Canada
BTIG reiterates Lucid Diagnostics stock rating on Q4 beat - Investing.com
Lucid Diagnostics Inc. (LUCD) reports Q4 loss, beats revenue estimates - MSN
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Lucid Diagnostics non-GAAP adjusted loss hits USD 12.6M in Q4 2025 - Medical Buyer
Lucid Diagnostics (NASDAQ:LUCD) Rating Increased to Hold at Wall Street Zen - MarketBeat
Valuation Update: What is the long term forecast for Lucid Diagnostics Inc stockQuarterly Trade Review & Stepwise Trade Execution Plans - baoquankhu1.vn
PAVmed (PAVM) outlines going concern risk, Nasdaq compliance and growth plans - stocktitan.net
Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2025 Earnings Call Transcript - Insider Monkey
[EFFECT] Lucid Diagnostics Inc. SEC Filing - Stock Titan
Lucid Diagnostics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-03-27 - Seeking Alpha
Lucid Diagnostics signals expanded VA market access and 29% sequential test volume growth while targeting Medicare and commercial payer wins - MSN
Lucid Diagnostics Reports 2025 Financial Results, Expands EsoGuard Access with VA Contract and Positive Real-World Data - Minichart
Lucid Diagnostics (NASDAQ: LUCD) launches ATM program to sell up to $25M - Stock Titan
Lucid Diagnostics Inc (LUCD) Q4 2025 Earnings Call Highlights: Strong Test Volume Growth and ... By GuruFocus - Investing.com Canada
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com Australia
The Dixie Group Q4 2025 Financial Review - AlphaStreet
Lucid Diagnostics Q4 2025 Earnings Call Transcript - MarketBeat
Lucid Diagnostics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham & Company LLC Reiterates Buy Rating for Lucid Diagnostics (NASDAQ:LUCD) - MarketBeat
Needham reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
LUCD: Test volume and revenue surged, with Medicare and VA poised to drive future growth - TradingView
Lucid Diagnostics Provides Business Update and Reports Fourth Qu - GuruFocus
Lucid Diagnostics Inc. (LUCD) Reports Q4 Earnings - AlphaStreet
LUCD: Strong Q4 growth, VA contract, and imminent Medicare coverage position for accelerated revenue - TradingView
Lucid Diagnostics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Lucid Diagnostics Q4 2025 sees stock rise despite EPS miss By Investing.com - za.investing.com
Earnings call transcript: Lucid Diagnostics Q4 2025 sees stock rise despite EPS miss - Investing.com
Lucid Diagnostics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Lucid Diagnostics reports Q4 revenue of $1.5M, VA contract By Investing.com - in.investing.com
Canaccord reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - in.investing.com
Lucid Diagnostics Reports Q4 2025 Results, Highlights VA Contract - TipRanks
Lucid Diagnostics reports Q4 revenue of $1.5M, VA contract - investing.com
Canaccord reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
Lucid Diagnostics (Nasdaq: LUCD) reports 2025 loss, VA contract win - Stock Titan
Press Release: Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Lucid Diagnostics (NASDAQ: LUCD) adds $25M ATM to $175M shelf - Stock Titan
Lucid Diagnostics Inc. (LUCD) Stock Rises on Q4 2025 Earnings - quiverquant.com
Lucid Diagnostics 2025 10-K: Revenue $4.7M, Net Loss $58.0M - TradingView
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lucid Diagnostics Inc Stock (LUCD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Matheis Dennis | Director |
May 20 '25 |
Buy |
1.29 |
187,098 |
242,292 |
187,098 |
| Matheis Dennis | Director |
May 21 '25 |
Buy |
1.32 |
129,684 |
171,520 |
316,782 |
| Matheis Dennis | Director |
May 22 '25 |
Buy |
1.32 |
33,218 |
43,795 |
350,000 |
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):